12月7日，2025上证（巢湖）上市公司高质量发展大会在安徽合肥举办。图为会议期间举行的2025"上 证鹰·金质量"颁奖仪式 ◎记者 孙小程 闫婧 改革提速 资本活水赋能创新 风起巢湖，科创潮涌。 在中国经济迈向高质量发展新阶段的关键时期，上市公司作为实体经济的"基本盘"与产业创新的"领头 雁"，肩负着培育新质生产力、驱动产业升级的时代使命。如何以资本市场之力激活创新动能，以制度 创新护航上市公司行稳致远？ 12月7日，2025上证（巢湖）上市公司高质量发展大会在安徽合肥举办。大会由中国上市公司协会指 导，上海证券报·中国证券网主办，华安证券联合主办，古井贡酒全程支持，上海财经大学、上海交通 大学上海高级金融学院、中国科学技术大学科技商学院、南开大学中国公司治理研究院、长三角（安 徽）资本市场学院提供学术支持。 大会以"资本赋能科创，产业引领未来"为主题。来自地方政府、监管部门、上市公司、优强企业、金融 机构和高校院所等领域逾1200位嘉宾参会，共同谋划上市公司高质量发展的新蓝图。会议期间还举行了 2025"上证鹰·金质量"颁奖仪式。 会上，上海证券报社联合上海财经大学共同编著的《上市公司高质量发展报告（20 ...

Market Performance - The chemical products sector increased by 0.35% on December 5, with Fengguang Co. leading the gains [1] - The Shanghai Composite Index closed at 3902.81, up 0.7%, while the Shenzhen Component Index closed at 13147.68, up 1.08% [1] Top Gainers in Chemical Sector - Fengguang Co. (301100) closed at 23.68, up 9.17% with a trading volume of 39,700 shares and a transaction value of 91.2591 million yuan [1] - Huaheng Biological (688639) closed at 33.78, up 6.93% with a trading volume of 89,300 shares and a transaction value of 29.567 million yuan [1] - Fulainte (605566) closed at 32.04, up 6.09% with a trading volume of 33,200 shares and a transaction value of 104 million yuan [1] Sector Fund Flow - The chemical products sector experienced a net outflow of 579 million yuan from institutional investors, while retail investors saw a net inflow of 901 million yuan [2] - The top stocks with significant fund flow include Wanhua Chemical (600309) with a net inflow of 34.4 million yuan from institutional investors [3] - Jiangnan Chemical (002226) had a net inflow of 20.2273 million yuan from institutional investors, while retail investors experienced a net outflow of 2.10932 million yuan [3]

（原标题：国投、招商局参与 生物制造领域唯一国家级产业创新中心试运行） 21世纪经济报道记者 陈思琦 深圳报道 深圳迎又一国家级平台落地。 12月4日，在由深圳市政府主办的"光明科学城论坛·2025"开幕式上，国家生物制造产业创新中心启动试 运行。据悉，该中心由中国科学院深圳先进技术研究院牵头组建，是我国生物制造领域唯一的国家级产 业创新平台。 会上介绍，中心将围绕绿色低碳、生物农业、医疗健康三大领域，建设自动化生物制造平台、跨尺度生 物多模态验证平台、生产工艺高通量开发平台、中试放大及GMP平台、大规模载体制备与质控平台、 生物信息计算支撑平台等六大技术平台，助力实验室创意进入新产品创制的"0—1—10"进程。 当前，深圳已集聚合成生物研究重大科技基础设施、深圳市工程生物产业创新中心、深圳理工大学合成 生物学院等各类产学研平台。《深圳市生物制造发展白皮书（2025）》显示，近三年，中国每新成立 100家生物制造企业，就有40家在深圳，其中30家在光明区。 事实上，参与共建的两大央企，对生物制造领域的关注和布局由来已久。 招商局集团官网显示，集团牵头承担国务院国资委焕新行动生物制造专项，"系列生物基聚酰胺开发 ...

Industry Overview - The chemical sector's overall performance ranked 13th this week (2025/11/24-2025/11/28) with a change of 2.98%, positioned in the upper-middle of the market. The Shanghai Composite Index rose by 1.40%, while the ChiNext Index increased by 4.54%. The Shenwan Chemical sector outperformed the Shanghai Composite by 1.58 percentage points but underperformed the ChiNext by 1.56 percentage points [1]. Key Insights - The chemical industry is expected to continue its trend of divergence in 2025, with recommendations to focus on synthetic biology, pesticides, chromatography media, sweeteners, vitamins, light hydrocarbon chemicals, COC polymers, and MDI [1]. Synthetic Biology - A pivotal moment for synthetic biology is anticipated, driven by energy structure adjustments. Traditional chemical companies will face competition based on energy consumption and carbon tax costs. Companies that adopt green energy alternatives and leverage integrated and scaled advantages are likely to reduce energy costs and expand into larger overseas markets. The demand for bio-based materials is expected to surge, leading to potential profitability and valuation increases. Key companies to watch include Kasei Bio and Huaheng Bio [1]. Refrigerants - The implementation of quota policies is expected to usher in a high-growth cycle for third-generation refrigerants. Starting in 2024, the supply of these refrigerants will enter a "quota + continuous reduction" phase, while second-generation refrigerants will be phased out more rapidly. The demand for refrigerants is projected to grow steadily due to the development of heat pumps, cold chain markets, and the expansion of the air conditioning market in Southeast Asia. Companies with high quota shares, such as Juhua Co., Sanmei Co., Haohua Technology, and Yonghe Co., are expected to benefit significantly [2]. Electronic Specialty Gases - Electronic specialty gases are critical to the electronics industry and represent a core component of domestic industrialization. The domestic market is experiencing rapid upgrades in wafer manufacturing, but there is a mismatch with the fragmented and insufficient capacity of high-end electronic specialty gases. Companies that establish high-end capacity and possess substantial technical reserves are likely to seize opportunities for growth. Demand is driven by integrated circuits, displays, and photovoltaics. Key players include Jinhong Gas, Huate Gas, and China Shipbuilding Gas [3]. Light Hydrocarbon Chemicals - The trend towards light raw materials in the global olefin industry has been significant over the past decade, with a shift from heavy naphtha to lighter low-carbon alkanes like ethane and propane. This transition is characterized by shorter processes, higher yields, and lower costs. Light hydrocarbon chemicals also align with global low-carbon and energy-saving initiatives. Companies in this sector, such as Satellite Chemical, are expected to see their values reassessed [4]. COC Polymers - The industrialization of COC/COP (cyclic olefin copolymer) is accelerating in China, driven by domestic companies achieving breakthroughs after years of R&D. The shift of downstream industries, such as consumer electronics and new energy vehicles, to domestic sources is increasing the demand for these materials. The market is currently constrained by high prices, but domestic companies are expected to break through and expand market space. Key company to watch is Acolyte [5]. Potash Fertilizers - Potash fertilizer prices are expected to rebound as the industry enters a destocking cycle. Canpotex has withdrawn new quotes, and Nutrien has announced production cuts, leading to a short-term decline in supply. The termination of the Black Sea Grain Export Agreement has increased the prices of wheat and corn, boosting the demand for potash fertilizers. Companies like Yara International, Salt Lake Potash, and Zangge Mining are positioned to benefit from this trend [6]. MDI Market - The MDI market is characterized by oligopoly, with demand steadily improving due to the expansion of polyurethane applications. The global MDI production capacity is concentrated among five major chemical giants, which account for 90.85% of total capacity. Despite current price fluctuations, MDI remains a high-margin product. Companies like Wanhua Chemical are expected to benefit from a favorable supply structure as demand recovers [7]. Price Tracking - The top five price increases this week included methanol (East China) at 6.27%, NYMEX natural gas (futures) at 5.90%, and caprolactam (East China CPL) at 5.49%. The top five price decreases included liquid chlorine (East China) at -7.82% and propylene oxide (East China) at -5.85% [8]. Supply Side Tracking - This week, 168 chemical enterprises had their production capacities affected, with 9 new repairs and 3 restarts reported [9].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 12 月 02 日（星期二）至 12 月 08 日（星期一）16:00 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ahb@ehuaheng.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 安徽华恒生物科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告。为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 月 09 日（星期二） 09:00-10:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 证券代码：688639 证券简称：华恒生物 公告编号：2025-053 安徽华恒生物科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 董事、副总经理、财务负责人樊义先生； 独立董事陈继忠先生； 董事会秘书邓先河先生。 本次投资者说明会以 ...

Group 1 - The 14th Five-Year Plan emphasizes high-quality development in the defense and military sectors, focusing on the construction of unmanned intelligent combat forces and enhancing military system operational efficiency [1] - The plan aims to achieve the centenary goal of building a strong military by accelerating the development of advanced combat capabilities and modernizing military governance [1] - Key areas of focus include improving national security capabilities in emerging fields such as cyber, data, artificial intelligence, and space [1] Group 2 - The demand for AI, commercial aerospace, and large aircraft is expected to rise, with Nvidia's CEO announcing $500 billion in orders for upcoming chip series [2] - Malaysia Airlines is evaluating the C919 aircraft from COMAC as a potential addition to its fleet, indicating growing interest in new aircraft models [2] - Domestic companies are successfully producing GaN power amplifier chips for mobile devices, with over 1 million units delivered, highlighting advancements in consumer electronics [2] Group 3 - Investment opportunities are identified in companies benefiting from domestic demand and overseas expansion, including AVIC Shenyang Aircraft, AVIC Xi'an Aircraft, and others [3] - The military AI-driven information technology upgrade presents opportunities across the entire supply chain, with companies like Ruichuang Micro-Nano and AVIC Optoelectronics highlighted [3] - The civil aviation sector's capacity expansion and opportunities in large aircraft and controllable nuclear fusion are noted, with a focus on companies like Aero Engine Corporation and China Power [3]

Investment Rating - The industry investment rating is "Overweight" [1] Core Views - The chemical sector overall experienced a decline of 7.47% during the week of November 17-21, 2025, ranking 29th among all sectors, underperforming the Shanghai Composite Index by 3.57 percentage points [4][22] - The report highlights a continued trend of divergence in the chemical industry for 2025, recommending focus on sectors such as synthetic biology, pesticides, chromatography media, sweeteners, vitamins, light hydrocarbon chemicals, COC polymers, and MDI [4] Summary by Sections Industry Performance - The chemical sector's performance was notably poor, with the Shanghai Composite Index declining by 3.90% and the ChiNext Index by 6.15% during the same period [4][22] - The report indicates that the chemical sub-sectors showed varied performance, with the least decline in refining chemicals (-0.58%) and the most significant decline in fluorinated chemicals (-11.00%) [23] Key Industry Dynamics - The report discusses the upcoming quota policies for refrigerants, which are expected to enter a high prosperity cycle starting in 2024, with a continuous reduction in supply for second-generation refrigerants [5] - The electronic specialty gases market is highlighted as a critical area for domestic substitution opportunities due to high technical barriers and increasing demand from semiconductor and photovoltaic sectors [6][8] - The light hydrocarbon chemical trend is identified as a global movement, with a shift towards lighter raw materials for olefin production, which is expected to enhance the valuation of leading companies in this sector [8] - The COC polymer industry is experiencing accelerated domestic industrialization, driven by the shift of downstream industries to domestic production and the need for supply chain security [9] - The potassium fertilizer market is anticipated to rebound as major producers reduce output, leading to a potential recovery in prices [10] - The MDI market is characterized by oligopoly, with a favorable supply structure expected as demand gradually recovers [12]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for 10 companies seeking to list in Hong Kong, indicating a rigorous review process for overseas listings by Chinese firms [2][5][7]. Group 1: Regulatory Requirements - Chinese companies must obtain a filing notice from the CSRC before listing in Hong Kong, and this notice must be submitted at least four business days prior to the listing hearing [2]. - The CSRC's International Department has requested additional information from companies including Micro Manufacturing, Rongtai Pharmaceutical, and others regarding their compliance with regulatory guidelines [2][5]. Group 2: Company-Specific Inquiries - **Micro Manufacturing**: The company is required to clarify the reasons for inconsistencies in the identification of controlling shareholders and provide legal opinions on the matter [2]. Additionally, it must explain the reasonableness of the share prices for new shareholders over the past 12 months and whether there are any issues of interest transfer [2][3]. - **Rongtai Pharmaceutical**: Similar to Micro Manufacturing, it must justify the share prices for new shareholders and confirm compliance with regulatory guidelines regarding its business operations [5][6]. - **Hua Heng Biological**: The company needs to provide details on its technology export activities and confirm compliance with regulations prohibiting certain overseas listings [7][8]. - **Magic Vision Technology**: The company is asked to clarify the pricing basis for share transfers and the legality of its historical equity changes [9][10]. - **Wangyuan Technology**: The company must explain the rationale behind share transfer pricing and the implications of its previous A-share listing application [13][14]. - **Jingchen Semiconductor**: The company is required to provide updates on its capital changes and the operational status of its subsidiaries [18][19]. - **Changchun High-tech**: The company must clarify the ownership structure of its controlling shareholders and the implications of any share pledges [20][21]. - **Inpai Pharmaceutical**: The company needs to address the pricing basis for its equity changes and confirm compliance with foreign investment regulations [25][26]. - **Puyuan Precision Electronics**: The company is required to clarify its overseas investment compliance and the operational status of its subsidiaries [27][28]. - **Aimeson**: The company must provide details on its historical equity changes and the implications of its shareholder structure on compliance with foreign investment regulations [29][30].

11月24日，华恒生物涨5.3%，截至发稿，报33.98元/股，成交2.13亿元，换手率2.55%，总市值84.99亿 元。 资料显示，安徽华恒生物科技股份有限公司位于安徽省合肥市高新区长安路197号,香港铜锣湾希慎道33 号利园1期19楼1901室，成立日期2005年4月13日，上市日期2021年4月22日，公司主营业务涉及氨基酸 及其衍生物产品研发、生产、销售。主营业务收入构成为：氨基酸系列70.96%，其他(补充)20.96%，维 生素系列5.34%，其他产品2.74%。 从华恒生物十大流通股东角度 数据显示，交银施罗德基金旗下1只基金位居华恒生物十大流通股东。交银先进制造混合A（519704） 三季度减持383.68万股，持有股数431.35万股，占流通股的比例为1.72%。根据测算，今日浮盈赚取约 737.61万元。 交银先进制造混合A（519704）成立日期2011年6月22日，最新规模44.97亿。今年以来收益35.48%，同 类排名1407/8209；近一年收益33.53%，同类排名1278/8129；成立以来收益793.9%。 交银先进制造混合A（519704）基金经理为郭若。 截至发稿，郭 ...

Core Insights - The global amino acid industry has undergone three key technological iterations since its industrialization in the early 20th century, with Japan historically leading the technology direction through companies like Ajinomoto and Degussa [1] - China's amino acid industry, initially constrained by reliance on imported core strains and lack of patents, is now shifting the global technology focus towards itself due to rapid advancements in synthetic biology and technological innovations [1][2] - The acquisition of the amino acid business from Kyowa Hakko by Meihua Biotechnology marks a significant transfer of technology and capabilities, allowing Chinese companies to enter the high-margin pharmaceutical amino acid market [2][4] Industry Dynamics - The decline of Japan's fermentation industry and the migration of technology have accelerated the shift of industry leadership towards China, with Japanese companies unable to sustain higher investments due to rigid cost structures and market contraction [1][3] - Meihua Biotechnology's acquisition provides it with a complete technical system for pharmaceutical-grade amino acids, including chassis strains and quality systems, positioning it strongly in a market where Kyowa Hakko holds over 40% market share in critical amino acids [2][3] - The Chinese amino acid industry is expected to expand its production capacity significantly, with lysine production projected to reach 3.47 million tons and output at 2.82 million tons in 2024, reflecting over a 50% increase from five years ago [2] Global Supply Chain Changes - China's amino acid exports have increased for five consecutive years, with lysine exports expected to reach 1.1062 million tons in 2024, accounting for nearly 40% of total production [3] - The global market is increasingly reliant on China's supply chain for cost, supply security, and high-end product demands, indicating a shift from a "China-Japan-Korea triangle" to a "China dual-pole" supply structure [3] - The transfer of technological sovereignty is expected to further alter the competitive landscape of the global amino acid industry, with Chinese companies gaining a dominant position in the market [3][4] Competitive Landscape - The amino acid industry has traditionally been characterized by cyclicality and cost competition, but the current technological transformation emphasizes the importance of comprehensive production capabilities [4] - Meihua Biotechnology's acquisition of Kyowa Hakko's pharmaceutical-grade products positions it at the core of the global pharmaceutical amino acid supply chain, showcasing a pathway for Chinese companies to achieve technological leaps through mergers and acquisitions [4]